Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.900 +0.080 (+0.91%)
Official Closing Price Updated: 8:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
39 40 Next >
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 7.70% at $0.78 
Via Benzinga
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs. 
Via Benzinga
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Cybin Inc. (NEO:CYBN) (NYSE American: CYBE) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”)... 
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 9.47% at $0.72 
Via Benzinga
New Research Finds That Individuals Prefer Guide with Personal Psilocybin Experience
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical’s DMT Clinical Study
Via Investor Brand Network
Cybin Acquires DMT Clinical Study from Entheon Biomedical
From Cybin Inc.
Via Business Wire
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.55% at $0.36 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Adelia Has Reached Milestone Achievements
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievements
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From June 3, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.88% at $0.35 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Spotlighted in “Frontiers in Psychology” Article
Via Investor Brand Network
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
From Cybin Inc.
Via Business Wire
Cybin, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 9.50% at $0.75 
Via Benzinga
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics Landscape, Current and Emerging Therapeutics
Via Investor Brand Network
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
From Cybin Inc.
Via Business Wire
ATAI Life Sciences, Intelgenx Technologies Among Top Psychedelic Movers Of Today
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 7.05% at $0.91 
Via Benzinga
Oregon Adopts First Installment of Psilocybin Rules
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From May 31, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 8.54% at $0.36 
Via Benzinga
Major Depressive Disorder Could Soon Have Treatment Option Via Cybin's Psilocybin Analog
Cybin Inc. (CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics," has submitted an Investigational New Drug (or “IND”) application to the FDA. 
Via Benzinga
How Your Mental Health May Benefit from a Digital Detox
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Major Step in Advancement of CYB003 for the Treatment of Major Depressive Disorder
Via Investor Brand Network
Exposures Product Safety
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain
Via Investor Brand Network
Exposures COVID-19
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder
From Cybin
Via Business Wire
Psychedelic Compounds-Based Stocks Continue To Decline
Our index tracks 6 of the largest clinical-stage startups, which have an average market capitalization of $65.5M and an average stock price of $0.69/share. 
Via Talk Markets
VC Executive Shares Insights into Legal Psychedelics Landscape
Via Investor Brand Network
Exposures COVID-19
Psychedelic Stock Gainers And Losers From May 26, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 21.06% at $0.34 
Via Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds
Via Investor Brand Network
TripAdvisor, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: TripAdvisor (NASDAQ:TRIP) shares closed up 6.06% at $23.45 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback